Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Identification of predictive protein signatures of treatment-free remission in patients with chronic myeloid leukaemia

View Full Paper
Ask AI
Bookmark
Share

Authors

JCJohn ColeRCRichard E. Clark

Discussion

Loading...

Member takes

Overview

Analysis uncovers protein signatures linked to treatment-free remission in chronic myeloid leukaemia, suggesting immune response implications.

Key Points

  • The aim is to identify predictive protein signatures associated with treatment-free remission in chronic myeloid leukaemia.
  • Bone marrow samples analyzed using mass spectrometry
  • Comparison of proteins from treatment-free remission and molecular recurrence groups
  • Gene ontology and gene set enrichment analyses conducted
  • Molecular profiling of mesenchymal stem cells performed
  • 72% of MR4 and 36% of MR3 patients maintained treatment-free remission after TKI cessation
  • Identification of differentially expressed proteins related to immune response and metabolic processes
  • Downregulation of proteins associated with humoral immune response linked to recurrence
  • Upregulation of proteins in metabolic pathways in molecular recurrence cases

Cite This Study

Cole et al. (2025) studied this question.

synapsesocial.com/papers/69362f604fa91c937236dd60https://doi.org/10.1182/blood-2025-1992
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Intronic DNA variants in EZH2 and GATA2 predict treatment-free remission in chronic myeloid leukemia patients from the destiny trial2025
  2. 2Development and External Validation of a Transcriptome-Based Multivariable Prediction Model for Treatment-Free Remission in Chronic Myeloid Leukemia2026
  3. 3BCR::ABL1 evaluation in bone marrow is no more predictive of TFR success than from peripheral blood2025
  4. 4A single-cell atlas of diagnostic bone marrow to uncover the origins of CML relapse following therapy cessation2025
  5. 5Comprehensive molecular characterization of treatment-free remission and molecular relapse in chronic myeloid leukemia patients: the EURO-SKI Biomarker Study2026 · 2 citations